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Breast lymphoma
A clinical and pathological review and
1O-year treatment results
S. Ariad, D. Lewis, R. Cohen, W. R. Bezwoda
Sixteen patients presenting with lymphoma involving the
breast are described. Seven fulfilled the criteria for primary
breast lymphoma, while the other 9 had evidence
(sometimes only detected after extensive staging
procedures) of concurrent lymphomatous involvement
outside the breast. Histological diagnoses of the so-called
primary breast lymphomas included 1 case of Hodgkin's
disease and 6 of non-Hodgkin's lymphoma (inclUding 2
with T-cell phenotypes). The patients with so-called
secondary breast involvement included 8 with non-
Hodgkin's lymphoma and 1 with a plasmacytoma of the
breast with concomitant myelomatous involvement of
bone marrow. Among the non-Hodgkin's lymphomas
involving the breast the whole range of histological
subtypes from low-grade to high-grade lesions were seen.
There was no subtype of lymphoma with a specific
predilection for breast involvement. Expression of
oestrogen receptor protein as determined by
immunocytochemical investigation using specific
monoclonal antibodies was uniformly negative in lymphoid
cells of 11 patients studied. Most of the patients in this
series were treated by chemotherapy with uniformly good
local control of lymphomatous involvement of the breast
and an outcome similar to that of lymphomas presenting
at other body sites. It is concluded that the approach to
lymphomas of the breast should be similar to that of the
equivalent types presenting elsewhere.
S Afr Med J 1995; 85: 85-89.
Lymphoma of the breast is a rare tumour constituting an
estimated 0,04 - 0,5% of all malignant breast lesions.'"
Wiseman and Lia02 proposed that lymphomatous breast
lesions be classified into primary and secondary breast
lymphoma. To fulfil the criteria for primary breast lymphoma,
the following characteristics were reqUired: (I) technically
adequate specimens; (iI) mammary tissue and
lymphomatous infiltrate in close association; (iil) no evidence
of concurrent widespread disease; and (iv) no previous
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diagnosis of extramammary lymphoma. Cases that did not
fulfil these criteria were classified as secondary breast
lymphomas.
While this classification has been fairly widely accepted, a
number of questions regarding lymphomatous breast
involvement remain unanswered. Firstly, is classification into
primary or secondary breast lymphomas truly of value from
a pathological, a clinical, or a prognostic point of view? It is
also not established whether there is any specific pattern of
lymphoma that shows predilection for breast involvement. In
this regard it has been suggested that lymphomatous
involvement of the breast is a specific entity, namely
mucosa-associated lymphoid tissue (MALT cell) lymphoma.'·7
Another question that has been raised about breast
lymphoma is the possibility that their growth may be _
influenced by hormones.' This has been suggested by the
apparent finding of oestrogen binding in two patients with
breast lymphomas.
Finally, the approach to treatment of patients with breast
lymphomas remains controversial.
In an attempt to clarify some of these issues, the records
of patients who attended the Haematology/Oncology Clinic
at Johannesburg Hospital between January 1981 and
January 1991 with lymphoma involving the breast were
reviewed.
Patients and methods
Criteria for inclusion in this study included: (I) breast
involvement as the initial presenting clinical feature;
(i/) availability of adequate pathological material for review;
and (iil) availability of detailed clinical data, especially
staging investigations, on the patients under review.
Pathological review utilised 3 IJ sections stained with routine
haematoxylin and eosin and Masson trichrome stains as well
as a variety of immunocytochemical investigations, inclUding
leucocyte common antigen, epithelial membrane antigen
and cytokeratin tests. Phenotype studies included T- and B-
cell analysis using a panel of monoclonal antibodies.
Pathological classification was based on the working
formulation but included other specific diagnoses where
appropriate.
Immunocytochemical staining for oestrogen receptor
protein was performed where material was available, by
means of a modified immunocytochemical technique using
paraffin-embedded material partially digested with trypsin
and DNAse. The primary antibody utilised was derived from
the ABBOT ERICA kit (Abbot Diagnostics). The details of the
immunocytochemical method have been pUblished
elsewhere.' Quantitation·of ER was by the H-score method,
which includes assessment of both the intensity of staining
and the percentage of positive cells.·
During the period under review, 19 patients were identified
as having lymphoma with breast involvement. Of these, 16
met the criteria set out above for inclusion in the stUdy; the
other 3 either had insufficient clinical data or no material for
histological review. Of the 16 patients included, 7 met the
clinical and pathological criteria proposed by Wiseman and
Lia02 for a diagnosis of primary breast lymphoma, while the
other 9 had evidence of concurrent lymphoma at sites other
than the breast and regional nodes. All had undergone
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clinical and pathological staging procedures, including as a
minimum a full history and physical examination, chest
radiographs, computed tomography of the chest and
abdomen, and bone marrow aspiration and trephine biopsy.
In addition, all had a full blood count with differential count
and automated biochemical analysis, including tests of renal
and hepatic function. A number underwent additional
staging procedures, depending on specific clinical
indications. Four patients underwent staging laparotomy.
Results
Clinical characteristics
All the patients were female. Their ages ranged from 20 to
77 years, with a mean of 47 ± 15,9 years. In all, breast
involvement had been the initial and major clinical
manifestation. Eleven of the 16 presented with a localised
breast mass, with cutaneous ulceration in 1 case, and 5 with
diffuse swelling; 3 of the latter had features similar to
'inflammatory' breast carcinoma, with cutaneous erythema,
oedema and increased heat of the entire breast. There were
no instances of bilateral breast involvement at presentation.
Further clinical details are shown in Table I.
Pathological features (Table 11)
The majority of both primary and secondary lymphomas
(15 of the 16) were of the non-Hodgkin's type, but there was
1 case of Hodgkin's disease, localised to the breast, that
fitted the clinical criteria of primary breast lymphoma. The
majority (5) of the 7 so-called primary breast lymphomas
were of intermediate or high grade, according to the
Working FormUlation (inclUding the patient with peripheral
T-cell lymphoma - this lesion could best be described as
immunoblastic, high-grade lymphoma, according to the
Working FormUlation).
Table 11. Pathological features of 16 patients with breast lymphomas
Table I. Clinical features of 16 patients with breast lymphoma
Patient Age Size Regional Other
No. (yrs) (cm) nodes nodes Visceral
Localised involvement
1 44 4x4 Yes No Neg.
2 30 5 x 5 skin Yes No Neg.
ulceration
3* 20 4x4 Yes No Neg.
4 51 Diffuse Yes No Neg.
inflammatory
5 50 5x5 No No Neg.
6 70 Diffuse Yes No Neg.
7 26 Diffuse No No Neg.
inflammatory
Lymphoma of breast + distal sites
8 n 6x6 No Yes Neg.
9 33 4x4 Yes No BM+
10* 55 5x5 No No BM+
11* 62 5x6 No No S.+, BM+
12* 59 5x5 No No SB+
13 70 Diffuse Yes No L+.'
14t 52 Diffuse Yes No BM+
inflammatory
15 34 5x5 Yes Yes Neg.
16 39 5x5 No Yes BM+·
• Patient underwent staging laparotomy.
t Patient had previous adenocarcinoma of left breast 9 yrs before presentation with
lymphoma of right breast
BM+ ~ bone marrow involvement; S+ ~ splenic involvement; L+ ~ pUlmonary
involvement, SB+ ~ small-bowel involvement (histological).
Among the secondary lymphomas with breast
involvement, intermediate and high-grade non-Hodgkin's
lymphomas also predominated. This group, however,
included 1 patient with an extramedullary plasmacytoma
involving the breast, who was found to have bone marrow
involvement with mUltiple myeloma on further investigation.
The diagnosis of mUltiple myeloma was only made after
histological diagnosis of plasmacytoma.
Pathologic Vascular ancl/or Infiltration of ducti
Patient No. classification Phenotype lymphatic invasion Sclerosis acinar epithelial layer
Localised involvement
1 DL Tcell Vascular +++ +++ Pos.
2 PTL Tcell Dermal Iymphatics Neg. Neg.
3 HO Neg. Neg. Neg.
4 DL Vascular + angiocentric ++++ Neg.
5 BL B cell Vascular ++ ++ Pos.
6 OS B cell Venous +++ Neg. Neg.
7 DL B cell Neg. Neg. Pos.
Lymphoma of breast + distal sites
8 OS (plasmacytoid) Neg. ++++ Neg.
9 Plasmacytoma B cell Neg. Neg. Neg.
10 OS B cell Neg. Pos.
11 OM B cell Vascular ++ Neg. Pos.
12 DL B cell Vascular ++ +++ Pos.
13 HGU B cell Neg. Neg. Neg.
14 DL B cell Venous ++ ++
15 DL B cell Neg. ++ Neg.
16 HGU B cell Vascular ++ ++ Pos.
OL ~ diffuse large-cell lymphoma; PTL ~ peripheral T-cell lymphoma; HO ~ Hodgkin's disease; BL ~ Burkitt's lymphoma; OS ~ diffuse small-eelllymphocytic lymphoma; OM ~ diffuse
mixed small· and large-eell lymphoma; HGU ~ high-grade unclassifiable lymphoma.
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In both primary and secondary breast lymphoma, the
pattern of involvement at the edge of the tissue was
infiltrative even when the breast mass appeared clinically to
be discrete. Invasion of the mammary parenchyma and of
mammary adipose tissue occurred frequently, both in so-
called primary lesions and in cases with involvement of
tissues other than the breast. In addition, vascular and/or
lymphatic invasion occurred in 9 cases (56%). Other notable
histological features were the presence of sclerosis and
involvement of ductules and acini by lymphoma cells.
Sclerosis was present in approximately half (8) of the cases,
and in most instances consisted of a fairly dense fibrous
stroma surrounding areas of lymphoma involvement.
Invasion of the duct epithelial layer, giving rise to a so-called
Iympho-epitheliallesion, occurred in 7 cases (44%). Both
sclerosis and invasion of the epithelial layer occurred with
approximately equal frequency in primary and secondary
breast lymphomas. Background reactive lymphoid infiltration
of the normal breast tissue, when present, was generally
sparse and germinal centres were not found.
Immunophenotyping (available for 12 patients) showed 10
cases to be B-cell and 2 T-cell lymphomas. Both the
lymphomas, specifically typed as T-cell lymphomas, were in
the so-called primary group.
In 11 cases in which immunocytochemical investigation
for oestrogen receptor protein was performed, the result
was uniformly negative in tumour cells. The adequacy of the
immunocytochemical technique was confirmed by positive
findings in the adjacent and entrapped breast ducts and
lobules.
Treatment and prognosis
Details and results of treatment are shown in Table Ill. The
majority of patients received chemotherapy only, those with
diffuse large-cell or other high-grade lymphomas mostly
receiving primary therapy with CHOP (cyclophosphamide +
Table Ill. Therapy in primary breast lymphoma
adriamycin + vincristine + prednisolone), while patients with
low-gade lymphomas were treated either with single-agent
chlorambucil or with COPP (cyclophosphamide + vincristine
+ prednisolone + procarbazine). The patient with
plasmacytoma of the breast and evidence of bone marrow
infiltration with multiple myeloma was initially treated with
VAD (vincristine + adriamycin + dexamethasone), while the
patient with Hodgkin's disease involving the breast was
treated with MOPP/ABVD (nitrogen mustard + vincristine +
prednisolone + procarbazine, alternating with adriamycin +
DTIC + vinblastine + bleomycin).
Initial local control of the breast tumour, whether of the
primary or the secondary type, was achieved in all 16
patients. The breast involvement responded completely in all
patients, irrespective of the chemotherapeutic regimen
employed. The 2 patients classified as haVing a partial
response had evidence of persistent disease at other sites.
Local breast disease recurred in 5 patients (1 with primary
lymphoma and 4 with secondary breast lymphomas). All 3 of
the patients with low-grade lymphoma treated with either
chlorambucil alone or chlorambucil plus radiation therapy
showed evidence of local recurrence. The other 2 relapses in
the breast included the patient with plasmacytoma of the
breast treated with VAD (patient 9), and the patient with
Burkitt's lymphoma treated with an acute leukaemia
induction and maintenance regimen (patient 5). The patient
with plasmacytoma/multiple myeloma had complete clinical
regression of the breast plasmacytoma and partial response
of the myeloma (as determined biochemically by protein
immuno-electrophoresis of blood and urine). Regrowth of
the breast plasmacytoma was again the first evidence of
progression of her disease, followed by a later rise of the
serum paraprotein concentration. The patient with Burkitt's
lymphoma relapsed with bilateral breast involvement,
together with bone marrow infiltration. In only 1 instance
(patient 6 with primary breast lymphoma) was the breast the
sole site of recurrence. In 3 patients who relapsed (including
1 patient with primary breast lymphoma), sites other than
the breast were involved.
Duration of first
Patient No. Initial therapy. Response response (mo.)
1 CHOP CR 24+
2 CHOP CR 60+
3 MOPP/ABVD _ CR 60+
4 CHOP CR 48
5 L2 protocol CR 12
6 Chlor. CR 36
7 CHOP CR 38+
8 DXT + Chlor. PRt 7
9 VAD PR 9
10 Chlor. CR 24
11 CHOP CR 4
12 CHOP CR 120+
13 CHOP CR 12
14 CHOP CR 16+
15 CHOP CR 10







































• Achieved 2nd remission with MACOP-B. Died of disseminated fungal infection.
t Local control of breasf tumour. Persistent marrow infiltration.
CHOP = cyclophosphamide + adriamycin + vincristine + prednisolone; MOPP = nitrogen mustard + vincristine + prednisolone + procarbazine; ABVD = adriamycin + bleomycin +
vinblastine + DTIC; L2 protocol =6-week induction cycle of vincristine + prednisolone + adriamycin (weeks 2 and 4) + L·asparaginase consolidation; Chior. = chlorambucil; DXT =
deep X-ray therapy; VAD = vincristine + adriamycin + dexamethasone; COPP =cyclophosphamide + vincristine + prednisolone + procarbazine; Melph. + Pred. =melphalan +
prednisolone; Cyt.+ Pred. = cyclophosphamide + prednisolone; MACOP-B = methotrexate + adriamycin + vincristine + prednisolone + bleomycin; NOPE = mitoxantrone + vincristine
+ prednisolone + etoposide; CR =complete response; PR =partial response; LN = lymph node; BM =bone marrow; CNS =central nervous system; A = alive; D =dead.
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Fig. 1. Cumulative survival of patients with breast lymphoma.
Discussion
Duration of both response and survival were variable, as
would be expected from a group of patients with lymphoma
with heterogeneous histological type and staging. Disease-
free survival of patients with high-grade lymphomas with
breast involvement, treated with CHOp, varied from 14 to
over 120 months (median 48 months). Although 4 patients
with involvement of breast plus other extranodal sites
showed evidence of early relapse (between 4 and 10
months), this would be expected in view of the more
widespread nature of their disease. There was, however, no
statistically significant difference in overall survival of
patients with so-called primary lymphoma of the breast, and
those with secondary breast lymphomas with involvement
outside the breast (Fig. 1).
Lymphoma of the breast is a rare diagnosis.'D-l. During the
period under review, the 16 patients with breast masses
documented to be lymphomatous at histological
examination represented 1,8% (16 of 870) of all patients
and 3,4% (16 of 463) of all females with a diagnosis of
lymphoma. The distribution between so-called primary and
secondary lymphomas was found to be roughly equal. Of
female patients with extranodal presentation, 8,6% (16 of
187) had breast lymphoma. During the same period there
were 1 252 patients with breast carcinoma. In addition, there
were 7 patients with sarcomas involving the breast (2
malignant fibrous histocytoma, 3 cytosarcoma phalloides, 1
fibrosarcoma and 1 neuroblastoma), and 2 cases of
leukaemic involvement of the breast (2 M4 AML, 1 T-ALL).
While lymphoma of the breast represented only a small
proportion of malignant breast lesions (16 of 1 281; 1,25%),
it represented 62% (16 of 26) of all non-carcinomatous
malignant lesions of the breast. These figures are somewhat
higher than those reported in the literature, a difference
which may be related to referral patterns at this institution,
patients with unusual lesions such as breast lymphoma
being more likely to be referred to a specialist centre than
patients with breast carcinoma.
In this review we have attempted to address a number of
issues raised in the literature regarding breast lymphoma.
From the clinical point of view, while the presentation of
breast lymphoma is often similar to that of breast carcinoma
(including the occurrence of 'inflammatory' features), this
issue is usually readily resolved by histological examination.
More important is the question of whether the
classification into so-called primary and secondary breast
lymphoma has any value, over and above that of
distinguishing between localised and widespread lymphoma
(staging). In this regard it should be pointed out that, as is
evident with lymphomas presenting at other sites, a
proportion of patients will be found to have more
widespread involvement as a result of clinical or more
comprehensive radiological and pathological investigations.
This was certainly the case in the current series, where
clinical involvement of distal nodes was evident in only 3 of
9 patients eventually classified as having so-called
secondary breast lymphoma. Other sites of involvemept,
including visceral involvement, were detected only as'a
result of systematic staging procedures. .
If the distinction between primary and secondary breast
lymphomas and the related concept that primary breast
lymphomas represent a specific instance of MALT cell·
malignancy are to have any validity, they must be based on
specific pathological, immunohistological or biological
(including prognosis and response to treatment) features.
In this regard, however, there were no specific pathological
features that distinguished breast lymphomas from
lymphomas arising at other sites, or indeed that
distinguished between patients with lymphomatous
involvement confined to the breast, and those with more
widespread involvement. In both the patients with localised
lymphomas and those with breast involvement as part of
disseminated lymphoma, the predominant histological
subtype was diffuse large cell (type G, Working Formulation).
While this finding is in keeping with the results of other
series",2,5,." .." it should be pointed out that other types of
non-Hodgkin's lymphoma as well as other
Iymphoproliferative disorders were also observed in both
clinical groups. Infiltration of the epithelial layer of ducts and
of acini occurred in a number of cases, but this pattern was
not specific and occurred in a number of different
histological subtypes of lymphoma in both secondary and
so-called primary cases. Furthermore, the presence or
absence of infiltration of the ductal or acinar epithelial layer
appeared to have no influence on prognosis. Stromal
sclerosis or infiltration of the breast parenchyma was also of
no prognostic significance:2when examined in a
multivariate analysis.
Immunophenotyping results were also of limited value in
distinguishing between localised and disseminated
lymphomas with breast involvement. While a predominance
of 8-cell lymphomas was demonstrated, this is not
unexpected among patients with non-Hodgkin's lymphoma.
There were 2 cases of T-cell lymphoma (both in patients with
'primary' breast lymphoma). While the striking
angiocentricity demonstrated in case 6 might suggest (in the
absence of immunophenotyping) that this patient also had a
T-cell lymphoma, lt should be pointed out that significant
vascular invasion was also seen in a number of other
lymphomas typed as being of 8-cell origin. T-cell
604020
0--0 Secondary Breast Lymphoma













Volume 85 No.2 February 1995 SAMJ
SAMJ
ARTICLES
lymphomatous involvement of the breast has also been
described by Cohen and Brooks;' who found 1 case of
primary T-cell lymphoma of the breast. We were unable to
distinguish between B- and T-cell lymphomas on purely
histological criteria, since vascular invasion was also found
with B-cell immunophenotypes.
The occurrence of both Hodgkin's disease and 2 cases of
T-cell lymphoma among the 'primary' breast lymphomas
also argues against the concept that breast lymphomas
specifically represent MALT cell lymphomas and suggests
that, while the relative rarity of breast involvement may well
be related to the paucity of lymphoid tissue in the breast,
the full spectrum of malignant lymphomas may on occasion
be encountered at this site.
Immunohistochemical investigation did not reveal specific
oestrogen receptor protein in either lymphoid cells or
surrounding ~troma in any of the cases. Since
immunohistochemical detection of oestrogen receptor
protein has, in our hands, been positive in 95% of breast
cancers with oestrogen receptor binding of > 30 fmoVmg
protein as detected by ligand binding assays, it is unlikely
that oestrogen receptor protein is present in any of these
tumours at clinically significant concentrations.
Reported treatment regimens for patients with lymphoma
of the breast have varied. While a number of series have
suggested that these tumours should be treated as localised
primary extranodal lymphomas with surgery and local
radiation therapy,'8,2021 the risk of recurrence, even in stage
1E non-Hodgkin's lymphoma of the breast, appears
significant!'2224 Both the histological type and the extent of
the disease need to be taken into consideration. In the
present series, 7 of 11 patients with non-Hodgkin's
lymphoma of the breast had diffuse large-cell or other high-
grade lesions, and in only 1 of these was the lymphoma
staged as lE. This, together with the frequent finding of
vascular invasion, suggested to us that chemotherapy was
the most appropriate treatment modality. In the event none
of the patients who received CHOP therapy for diffuse large-
cell lymphoma had local recurrence in the breast. While the
small size of this and other series makes it difficult to make
firm recommendations with regard to treatment, the results
of the present series tend to indicate that the prognosis and
treatment of breast lymphomas are and should be similar to
those of equivalent types of lymphomas occurring at other
sites.
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Dokter en digter
Tussen jou en my
Kyk!
Die wynglas skommel rooi -
in die helder vog
ons onvas oe
Onthou jy?
Ek aan hierdie kant
jy aan die ander -
tussen ons,
die wyn;
rooi soos die najaar
belee soos verlange ...
Maar die gla5 -
voor ons dit in sy volheid
kon fynproe ...
kristalglas
is breekbaar soos die liefde
en die rooiwyn vlek
en herinneringe is rooibruin blare;
Maar, voor die winter wit
is dit eers herfs
en die 91as skommel rooi skadu's
voer dit breek
Ueb Sauermann
Hierdie gedig het in Tandem, 'n versameling verse deur Lieb Sauerrnann
en Johann de Jager (1992), verskyn.
SAMJ Volume 85 o. 2 February 1995
1---------------=------
